GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease.
GLP-1 受體激動劑和 SGLT2 抑制劑降低血糖並減少心血管疾病及糖尿病腎病的風險。
J Am Board Fam Med 2024-08-14
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
SGLT2 抑制劑與 GLP-1 受體激動劑在 2 型糖尿病中的腎臟與心血管效果比較。
J Am Coll Cardiol 2024-08-14
Alpha-cyclodextrin increases glucagon-like peptide-1 secretion in multiple models and improves metabolic status in mice.
Alpha-cyclodextrin 在多種模型中增加了胰高血糖素樣肽-1的分泌,並改善了小鼠的代謝狀態。
Food Chem 2024-08-14
Regulator of G-protein signaling expression in human intestinal enteroendocrine cells and potential role in satiety hormone secretion in health and obesity.
人類腸道內分泌細胞中 G 蛋白信號調控因子的表達及其在健康與肥胖中對飽腹激素分泌的潛在作用。
EBioMedicine 2024-08-14
Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis.
胰高血糖素樣肽 1 受體激動劑對心房顫動在導管消融後復發的影響:系統性回顧與統合分析。
Adv Ther 2024-08-14